Drawing for DBV TECHNOLOGIES

USPTO serial 79364820

DBV TECHNOLOGIES

Reviewed by CopyMark Law Group

Reg. 7390034Status 700Registered
Filing date
Status date
Registration date
May 21, 2024
Examiner
MARTIN, LIEF ANDREW
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with DBV TECHNOLOGIES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jennifer Sheehan Anderson

Jennifer Sheehan Anderson Bridge Intellectual Property Services PL143 CadyCenter, Ste. 209Northville, MI 48167UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Medicated adhesive devices in the nature of epicutaneous patches enabling the cutaneous or epicutaneous administration of pharmaceutical or medicated substances in dry form for humans and animals for the treatment and prevention of allergies, autoimmune, inflammatory and infectious diseases; epicutaneous patches containing powdered preparations for medical use for the treatment and prevention of allergies, autoimmune, inflammatory and infectious diseases; medicated occlusion patches in the nature of epicutaneous patches enabling the absorption of powdered medicated substances through the skin for the treatment and prevention of allergies, autoimmune, inflammatory and infectious diseasesACTIVE
010Medical apparatus, instruments and devices, namely, epicutaneous patches sold without medication for the cutaneous or epicutaneous administration of medicated or cosmetic substances in dry form for humans or animals; occlusion patch dispensers for medical use; medical instruments using the electrostatic properties of biocompatible media, namely, epicutaneous patches sold without medicationACTIVE
041Educational services for consumers and professionals in the field of immunotherapy, namely, organizing classes, seminars, programs, conferences, congresses, workshops in the field of immunotherapy; organizing and providing exhibitions for online educational purposes featuring interactive presentations and exhibitions in the field of immunotherapy; publishing periodicals, books, and guides in the field of immunotherapy; database publishing services, namely publishing of periodical journals containing printed databases in tabular form in the field of immunotherapy; providing information with respect to education in the field of immunotherapy via an online websiteACTIVE
042Medical and scientific research in the field of immunotherapy, namely, developing scientific methods for epicutaneous immunotherapy, to try to treat and prevent autoimmune, infectious and inflammatory diseases without prior preparation of the skin other than a simple rapid cleaning in order to leave the cell structure of the skin intact; scientific research in the field of allergy treatment and care; scientific research in the field of allergy treatment for the repeated application of treatments to patients' skin without prior preparation of the skin other than a simple rapid cleaning in order to leave the cell structure of the skin intact and thus avoid the passage of allergens into the blood; allergenic drug discovery services; medical and scientific research services, namely, developing methods for treating allergies via contact between allergens and skin immune cells; medical and scientific research services, namely, developing methods for the treatment and prevention of allergies, autoimmune, infectious and inflammatory diseases by applying patches to patients' unbroken skin without prior preparation of the skin other than a simple rapid cleaning in order to leave the cell structure of the skin intactACTIVE
044Medical services using desensitization methods on the principle of immunotherapy; medical treatment and prevention of allergies, inflammatory, autoimmune and infectious diseases through the administration of allergens, antigens using patches affixed to the patients' unbroken skin, thus avoiding the transfer of allergens into the blood; medical treatment and prevention of allergies, inflammatory, autoimmune and infectious diseases using epicutaneous methods of desensitization via immunotherapy; epicutaneous medical treatments and prevention of allergies, inflammatory, autoimmune and infectious diseases without prior preparation of the skin other than a simple rapid cleaning in order to leave the cell structure of the skin intact; medical consultancy in the field of desensitization to allergies with respect to desensitization to combat allergiesACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 30, 2024FINOFINAL DECISION TRANSACTION PROCESSED BY IB
Nov 9, 2024FICSFINAL DISPOSITION NOTICE SENT TO IB
Nov 9, 2024FIMPFINAL DISPOSITION PROCESSED
Aug 21, 2024FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 13, 2024ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB
Jun 15, 2024NREPNEW REPRESENTATIVE AT IB RECEIVED
May 21, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED
May 21, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 5, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 5, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 4, 2024GPNXNOTIFICATION PROCESSED BY IB
Feb 14, 2024OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 14, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 14, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 14, 2024OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 26, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jan 24, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jan 24, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 24, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 29, 2023RFNTREFUSAL PROCESSED BY IB
Aug 9, 2023RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 9, 2023RFRRREFUSAL PROCESSED BY MPU
Jul 5, 2023RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 4, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 29, 2023DOCKASSIGNED TO EXAMINER
Mar 21, 2023MAFRAPPLICATION FILING RECEIPT MAILED
Mar 17, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 9, 2023REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance